Fig. 1 · Structure
Documents & Downloads
Cergutuzumab amunaleukin
CEA-Targeted Immunocytokine
Cergutuzumab amunaleukin is a CEA-targeted immunocytokine composed of a monomeric carcinoembryonic antigen (CEA) conjugated to an IL-2 variant. This compound exhibits significant immunostimulatory and antineoplastic properties, making it a valuable tool in cancer research. It is primarily utilized for investigating the modulation of immune responses against tumors expressing CEA, facilitating the exploration of cancer immunotherapy strategies.
In Stock
Free Aliquoting for Your Order
Tell us your preferred amount per vial. We’ll confirm the options.
Specifications
| Manufacturer | Adooq Bioscience |
|---|---|
| CAS Number | 1509916-03-3 |
| Applications | CEA-Targeted Immunocytokine |
| Molecular Weight | 162.05 kDa |
| Synonyms | CEA-IL2v; RG 7813; RO 6895882 |
Storage & Solubility
In Vitro Solubility
Reported Solubility
No reported solubility data are available for this product.
Preparing Stock Solutions
| Concentration | |
|---|---|
Values use four significant digits. Prepare to the final solution volume; this is not the volume of solvent to add.
Stock preparation is unavailable for this product molecular weight.
Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.
Storage
Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.